High-dose metoclopramide as an antiemetic in patients receiving cis-platinum-based combination chemotherapy

E. Gez, R. Catane, L. Pfau, S. Biran

Research output: Contribution to journalArticlepeer-review

Abstract

Thirty-seven patients with advanced malignancies, who received cis-platinum-based combination chemotherapy, were evaluated for the antiemetic efficacy of high-dose metoclopramide. Most of the patients suffered from ovarian carcinoma. The dose of metoclopramide was 7.5 or 10 mg/kg per course. A total of 69 courses were given to 37 patients and in 22% of the courses, nausea and vomiting were eliminated altogether. In an additional 48% of the courses, a partial protection from chemotherapy-induced emesis was evident. No serious side effects were observed. The administration of high-dose metoclopramide is recommended for prevention of cis-platinum chemotherapy-induced emesis.

Original languageEnglish
Pages (from-to)18-22
Number of pages5
JournalGynecologic Oncology
Volume21
Issue number1
DOIs
StatePublished - May 1985
Externally publishedYes

Fingerprint

Dive into the research topics of 'High-dose metoclopramide as an antiemetic in patients receiving cis-platinum-based combination chemotherapy'. Together they form a unique fingerprint.

Cite this